Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Priority to CU20100005ApriorityCriticalpatent/CU20100005A7/en
Publication of CU20100005A7publicationCriticalpatent/CU20100005A7/en
Un compuesto de fórmula (I) o una de sus sales farmacéuticamente aceptables, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia, por ejemplo en el tratamiento de enfermedades proliferativas como el cáncer y en particular en enfermedades mediadas por una quinasa mTOR y una o más enzimas PI3K. ESPACIO PARA LA FÓRMULAA compound of formula (I) or a pharmaceutically acceptable salt thereof, processes for its preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative diseases such as cancer and in particular in diseases mediated by a mTOR kinase and one or more PI3K enzymes. FORMULA SPACE
CU20100005A2010-01-082010-01-08
DERIVATIVES OF PIRIMIDINE TRISUSTITUIDA FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CU20100005A7
(en)
Compounds derived from heteroaryl pyridone and substituted aza-pyridone, btk kinase inhibitors; pharmaceutical composition that includes them; process of preparation of the pharmaceutical composition; pharmaceutical kit; and use for the treatment of immune disorders, cancer, inflammation, neurological disorders, among others.
Compounds derived from [1,2,4] triazolo [1,5-a] pyridine, jak2 or fak inhibitors; pharmaceutical compositions comprising them; and its use for the treatment of a hyperproliferative disease.
DERIVATIVES OF ESTRA- 1,3,5 (10), 16- TETRAEN- 3- CARBOXIMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES